Iovance Biotherapeutics
San Carlos, California, United States · Biotechnology, Health Care, Therapeutics
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promi
Key facts
- Headquarters
- San Carlos, California, United States
- Employees
- 804
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (IOVA)
- Website
- www.iovance.com
- Company page
Recent activity at Iovance Biotherapeutics
- : SEC 8-K (8.01): On October 5, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation intended for use at healthcare conferences and for communications with analysts, shareholders, and other stakeholders. This corporate presentation, attached as Exhibit 99.1, reflects the latest information and strategic directions of the company and is designed to engage with investors and inform them about recent developments. This update is significant as it showcases the company's ongoing efforts to maintain transparency and share updates regarding its operations and future outlook.
- : Iovance Biotherapeutics Appoints Noah Berkowitz as Chief Medical Officer
- : SEC 8-K (8.01): On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press release updating its full year 2026 revenue guidance. This update is significant as it communicates the company's expected financial performance for the year, reflecting management’s assessment of market and operational conditions. The press release serves to inform investors and stakeholders about changes in anticipated revenue, which could impact stock performance and investor decisions. It represents proactive communication regarding the company’s financial outlook amid potentially changing market conditions.
- : SEC 8-K (8.01): On August 6, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation which will be used in various healthcare conferences for stakeholders including analysts and current stockholders. This update signifies the company's ongoing engagement with the financial community and reflects its current strategy and developments. The updated presentation, referenced as Exhibit 99.1, may include crucial updates on Iovance's business initiatives, recent advancements in their operations, and potential future directions. This event enhances communication with investors and may impact stockholder perceptions.
- : SEC 8-K (8.01): On August 6, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation for use at healthcare conferences and to communicate with analysts, stockholders, and other interested parties. The presentation aims to provide current updates on the Company's strategic goals and progress in biotherapeutic developments. A copy of this updated corporate presentation is attached as Exhibit 99.1. This event signifies Iovance's ongoing engagement efforts with stakeholders and reflects its commitment to transparency regarding its operations and future direction.
- : SEC 8-K (8.01): On June 30, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation that will be utilized for upcoming healthcare conferences, as well as for analysts and current shareholders. This update reflects the company’s latest strategic direction and key developments in its operations. The presentation, detailed in Exhibit 99.1 attached to the filing, is aimed at enhancing communication with stakeholders and potentially impacting investor sentiment. This communication is part of the company's ongoing efforts to keep its investors informed and engaged.
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On March 17, 2026, Wendy Yarno announced her retirement from the Board of Directors of Iovance Biotherapeutics, Inc., effective at the upcoming Annual Meeting scheduled for June 2026. Ms. Yarno's decision not to seek re-election was clarified as not owing to any disagreements with the Company regarding operational matters. Her retirement marks a significant change in the Board composition as the Company transitions into its next phase of governance. The Company expresses gratitude for her contributions during her tenure. This change may influence the strategic direction as new board members will be considered for appointment post the Annual Meeting.
- : SEC 8-K (8.01): On February 24, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation for use at healthcare conferences and to analysts, current stockholders, and others. The updated presentation is attached as Exhibit 99.2 and will be utilized at future events to enhance communication of the company’s strategic initiatives and developments. This update reflects the company's ongoing efforts to engage stakeholders effectively and ensure alignment with market expectations.
- : SEC 8-K (8.01): On January 9, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation for use at healthcare conferences and to analysts, stockholders, and others. The presentation highlights that the Company expects to achieve its previously disclosed full-year 2025 revenue guidance of $250 to $300 million, coinciding with the first full calendar year of Amtagvi sales. The updated materials are significant for stakeholders as they reaffirm the Company's financial outlook and strategic growth expectations. A copy of the presentation is attached as Exhibit 99.1.
Iovance Biotherapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2016 | Venture | $100.0M |
Leadership
- Wayne Rothbaum, Director
- Ryan Maynard, Director
- Sanford Hillsberg, Director
- Jay Venkatesan, Director
- Merrill McPeak, Director
- Maria Fardis, Executive Officer, Director
- Noah Berkowitz, Chief Medical Officer
- Dan Kirby, Chief Commercial Officer
- Steven Fischkoff, Executive Officer
- Michael Lotze, Executive Officer
- Molly Henderson, Executive Officer
Verified email and direct lines for Iovance Biotherapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Iovance Biotherapeutics files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Iovance Biotherapeutics in the news
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance (Oct 16, 2026)
- Iovance Highlights TIL Cell Therapy Platform Across Solid - GlobeNewswire (Oct 19, 2026)
- Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 - Yahoo Finance (Jul 30, 2026)
- Nearly 60% revenue growth is implied by Iovance's 2026 forecast. - Stock Titan (Sep 29, 2026)
- Iovance Biotherapeutics Reports Record Second Quarter 2026 - GlobeNewswire (Aug 06, 2026)
- Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire (Oct 01, 2026)
- Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 - GlobeNewswire (Jun 01, 2026)
- Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates - GlobeNewswire (May 07, 2026)
Companies similar to Iovance Biotherapeutics
- Lantheus Holdings · Biotechnology, Health Care, Therapeutics
- Innovent Biologics (Innovent) · Biotechnology, Health Care, Therapeutics
- Corcept · Biotechnology, Health Care, Therapeutics
- Edity Therapeutics · Biotechnology, Health Care, Therapeutics
- The Dion Foundation and Atamyo Therapeutics · Biotechnology, Health Care, Therapeutics
About Iovance Biotherapeutics: questions and answers
What does Iovance Biotherapeutics do?
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promi
Where is Iovance Biotherapeutics headquartered?
Iovance Biotherapeutics is headquartered in San Carlos, California, United States.
How many employees does Iovance Biotherapeutics have?
Iovance Biotherapeutics has about 804 employees.
Has Iovance Biotherapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Iovance Biotherapeutics. The most recent, $100.0M, was in Jun 2016.
What is the latest news on Iovance Biotherapeutics?
On Oct 05, 2026, SEC 8-K (8.01): On October 5, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation intended for use at healthcare conferences and for communications with analysts, shareholders, and other stakeholders. This corporate presentation, attached as Exhibit 99.1, reflects the latest infor
Is Iovance Biotherapeutics a public company?
Yes. Iovance Biotherapeutics is publicly traded under the ticker IOVA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy